Evidence map›Paper›PMID 39070357›Full record

ArticleCureus2024

Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers.

Felipe A Muñoz Rossi, Juanita Salazar Agudelo, Néstor Israel Quinapanta Castro, Sofía Z Mosquera, Maria Clara Mejia Fajardo, Edgar Dario Mosquera López, Jonathan Dany Espitia Olarte, Maria Andrea Figueroa Medina, Edwin Zuniga Simancas, Luis Fernando Saldarriaga Osuna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Felipe A Muñoz RossiInternal Medicine, National University of Colombia, Bogota, COL.
Juanita Salazar AgudeloEmergency Medicine, CES Clinic, Medellin, COL.
Néstor Israel Quinapanta CastroResearch and Biostatistics, Regional Autonomous University of the Andes, Ambato, ECU.
Sofía Z MosqueraEmergency Medicine, CES Clinic, Medellin, COL.
Maria Clara Mejia FajardoGeneral Medicine, Cooperative University of Colombia, Medellín, COL.
Edgar Dario Mosquera LópezGeneral Medicine, Universidad Central del Ecuador, Quito, ECU.
Jonathan Dany Espitia OlarteInternal Medicine, National University of Colombia, Bogota, COL.
Maria Andrea Figueroa MedinaGeneral Medicine, Libre University of Colombia, Barranquilla, COL.
Edwin Zuniga SimancasInternal Medicine, Sinu University/General Clinic of the Caribbean/Blas de Lezo Clinic/Cardiovascular and Metabolic Center, Cartagena, COL.
Luis Fernando Saldarriaga OsunaGeneral Physician, National University of Colombia, Bogota, COL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) primarily affects the adult population and is closely related to obesity. The most severe form of MASLD, metabolic dysfunction-associated steatohepatitis (MASH), can progress to liver fibrosis. While lipoprotein(a) (Lp(a)) is known to be associated with cardiovascular disease, its relationship with MASLD remains unclear. This study aims to determine the prevalence of MASLD in ambulatory patients and to explore the association between Lp(a) levels and advanced liver damage.

methodsThis retrospective cross-sectional study included 130 patients older than 18 years seen in a healthcare center in Medellin, Colombia, between April 2023 and May 2024. Sociodemographic, clinical, and specific biomarker data were collected. Patients with cirrhosis, previous liver disease, frequent alcohol consumption, cancer, and other severe conditions were excluded. Continuous variables were analyzed using Student's t-tests or Mann-Whitney tests according to their distribution, and categorical variables were analyzed using contingency tables and chi-square tests.

resultsOf the 130 patients, 57.9% (n=73) had MASLD, with a higher prevalence in patients with obesity (80%, n=32). Lp(a) levels were abnormally high in 43.1% (n=31) of patients; however, a weak but significant inverse correlation was found between Lp(a) levels and the Fibrosis-4 (FIB-4) score, which is used to assess the severity of liver fibrosis. Patients with MASLD had significantly lower high-density lipoprotein (HDL) and vitamin D levels, and higher levels of gamma-glutamyl transferase (GGT).

conclusionsThis study highlights the significant prevalence of MASLD in outpatients and its relationship with various biomarkers, including Lp(a), HDL, vitamin D, and GGT. Although the findings suggest a possible utility of Lp(a) as a biomarker in MASLD, longitudinal studies are needed to confirm these associations and clarify their role in liver disease progression. The study's limitations include its cross-sectional nature and potential selection bias, indicating the need for further research to validate these results.

Indexed as

gamma glutamyl transferase (ggt)high-density lipoproteins (hdl-c)lipoprotein (a)nash and steatosisnon-alcoholic fatty liver disease

Identifiers

PMID39070357
PMCPMC11276174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.